Author(s): Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL,
Abstract Share this page
Abstract Hypersensitivity to abacavir affects about 4\% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46\%) of 84 patients versus four (4\%) of 113 controls (p<0 small middle dot0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.
This article was published in Lancet
and referenced in Journal of Pharmacogenomics & Pharmacoproteomics